275 related articles for article (PubMed ID: 18454570)
21. Current treatments and future perspectives in colorectal and gastric cancer.
Wilke HJ; Van Cutsem E
Ann Oncol; 2003; 14 Suppl 2():ii49-55. PubMed ID: 12810459
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary nodules and metastases in colorectal cancer.
Nordholm-Carstensen A
Dan Med J; 2016 Jan; 63(1):B5190. PubMed ID: 26726908
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Moretto R; Corallo S; Belfiore A; Rossini D; Boccaccino A; Lonardi S; Centonze G; Morano F; Germani MM; Loupakis F; Morelli L; Urbani L; Brich S; Marmorino F; Prisciandaro M; Aprile G; Fassan M; Cillo U; Cattaneo L; Fontanini G; De Braud F; Falcone A; Milione M; Pietrantonio F; Cremolini C
Eur J Cancer; 2020 Aug; 135():78-88. PubMed ID: 32554314
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
26. AGA Clinical Practice Update on Young Adult-Onset Colorectal Cancer Diagnosis and Management: Expert Review.
Boardman LA; Vilar E; You YN; Samadder J
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2415-2424. PubMed ID: 32525015
[TBL] [Abstract][Full Text] [Related]
27. Advanced Mucinous Colorectal Cancer: Epidemiology, Prognosis and Efficacy of Chemotherapeutic Treatment.
Ott C; Gerken M; Hirsch D; Fest P; Fichtner-Feigl S; Munker S; Schnoy E; Stroszczynski C; Vogelhuber M; Herr W; Evert M; Reng M; Schlitt HJ; Klinkhammer-Schalke M; Teufel A
Digestion; 2018; 98(3):143-152. PubMed ID: 29870979
[TBL] [Abstract][Full Text] [Related]
28. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
29. Aberrant Partial Chromosomal Instability With Chemotherapeutically Resistant Metachronous Colorectal Cancer Following a Synchronous Primary Colorectal Cancer: A Case Report.
Dominic JL; Feroz SH; Muralidharan A; Ahmed A; Thirunavukarasu P
Cureus; 2020 Nov; 12(11):e11308. PubMed ID: 33282585
[TBL] [Abstract][Full Text] [Related]
30. Updated options for liver-limited metastatic colorectal cancer.
Alberts SR
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S58-62. PubMed ID: 19064408
[TBL] [Abstract][Full Text] [Related]
31. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A; Fakih M; Tabernero J
Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
[TBL] [Abstract][Full Text] [Related]
32. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
[TBL] [Abstract][Full Text] [Related]
33. [Influence of mucinous and signet-ring cell differentiation on epidemiological, histological, molecular biological features, and outcome in patients with colorectal carcinoma].
Benedix F; Kuester D; Meyer F; Lippert H
Zentralbl Chir; 2013 Aug; 138(4):427-33. PubMed ID: 22274919
[TBL] [Abstract][Full Text] [Related]
34. Current role of antibody therapy in patients with metastatic colorectal cancer.
Pfeiffer P; Qvortrup C; Eriksen JG
Oncogene; 2007 May; 26(25):3661-78. PubMed ID: 17530020
[TBL] [Abstract][Full Text] [Related]
35. Clinical and molecular features of young-onset colorectal cancer.
Ballester V; Rashtak S; Boardman L
World J Gastroenterol; 2016 Feb; 22(5):1736-44. PubMed ID: 26855533
[TBL] [Abstract][Full Text] [Related]
36. Second-line systemic therapy for metastatic colorectal cancer.
Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.
Koppe MJ; Boerman OC; Oyen WJ; Bleichrodt RP
Ann Surg; 2006 Feb; 243(2):212-22. PubMed ID: 16432354
[TBL] [Abstract][Full Text] [Related]
38. The increasing incidence of young-onset colorectal cancer: a call to action.
Ahnen DJ; Wade SW; Jones WF; Sifri R; Mendoza Silveiras J; Greenamyer J; Guiffre S; Axilbund J; Spiegel A; You YN
Mayo Clin Proc; 2014 Feb; 89(2):216-24. PubMed ID: 24393412
[TBL] [Abstract][Full Text] [Related]
39. Colorectal cancer in patients under the age of 40 years: experience from a tertiary care centre in the Czech Republic.
Kocián P; Whitley A; Blaha M; Hoch J
Acta Chir Belg; 2017 Dec; 117(6):356-362. PubMed ID: 28468569
[TBL] [Abstract][Full Text] [Related]
40. Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?
Rossi S; Basso M; Strippoli A; Schinzari G; D'Argento E; Larocca M; Cassano A; Barone C
Clin Colorectal Cancer; 2017 Dec; 16(4):264-274. PubMed ID: 28412137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
